Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Alcon, Alnylam, Penn, and More

Premium

Title: Compositions and Methods for siRNA Inhibition of Angiogenesis

Patent Number: 8,541,384

Filed: June 8, 2006

Lead Inventor: Michael Tolentino, University of Pennsylvania

The invention, the patent's abstract states, relates to "RNA interference using small interfering RNAs … specific for the vascular endothelial growth factor gene and the VEGF receptor genes Flt-1 and Flk-1/KDR [to] inhibit expression of these genes. Diseases [that] involve antiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age-related macular degeneration, and many types of cancer, can be treated by administering the small interfering RNAs."


Title: Chemically Modified Oligonucleotides for Use in Modulation of microRNA and Uses Thereof

Patent Number: 8,541,385

Filed: March 1, 2010

Lead Inventor: Markus Stoffel, Rockefeller University (Alnylam Pharmaceuticals)

"This invention relates generally to chemically modified oligonuceotides useful for modulating expression of microRNAs and pre-microRNAs," the patent's abstract states. "More particularly, the invention relates to single-stranded, chemically modified oligonuceotides for inhibiting microRNA and pre-microRNA expression and to methods of making and using the modified oligonucleotides. Also included in the invention are compositions and methods for silencing microRNAs in the central nervous system."


Title: RNAi-mediated Inhibition of Tumor Necrosis Factor-Alpha-related Conditions

Patent Number: 8,541,389

Filed: Feb. 25, 2011

Lead Inventor: John Yanni, Alcon

The invention relates to the use of "RNA interference for the inhibition of tumor necrosis factor-alpha by silencing TNF-alpha cell surface receptor TNF receptor-1 mRNA expression, or by silencing TNF-alpha-converting enzyme mRNA expression," the patent's abstract states. "Silencing such TNF-alpha targets, in particular, is useful for treating patients having a TNF-alpha-related condition or at risk of developing a TNF-alpha-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma."


Title: Treatment of Cancer by Inhibition of IGFBPs and Clusterin

Patent Number: 8,541,390

Filed: May 11, 2012

Inventor: Martin Gleave, University of British Columbia (OncoGenex Technologies)

The invention, the patent's abstract states, relates to "agents that reduce the amount of IGFBP-2 and/or IGFBP-5 and … result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. In overcoming this, the … invention provides a combination of therapeutic agents that is useful in the treatment of cancer. The combination includes an agent that reduces the amount of IGFBP-2 and/or IGFBP-5 and that stimulates expression of clusterin as a secondary effect, and an oligonucleotide that is effective to reduce the amount of clusterin in cancer cells."


Title: Compositions and Methods Using siRNA Molecules for Treatment of Gliomas

Patent Number: 8,541,568

Filed: March 16, 2011

Lead Inventor: Hai Yan, Duke University (Sirnaomics)

The invention provides "small interfering RNA molecules, compositions containing the molecules, and methods of using the compositions to treat gliomas," the patent's abstract states.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.